價(jià)格 | ¥3100 | ¥7180 | ¥9630 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-07-28 |
中文名稱:德格列哚 | 英文名稱:Deriglidole |
CAS:122830-14-2 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
純度規(guī)格: 98.24% | 產(chǎn)品類別: 抑制劑 |
貨號: T10998 |
名稱 | Deriglidole |
描述 | Deriglidole (SL 86-0715) is a peripheral adrenergic receptor antagonist that is a selective inhibitor of alpha2 receptors. Deriglidole inhibits colistin and Idazoxan but does not show activity against prazosin and rat cortical and human platelet α2-adrenergic receptors. |
體外活性 | Deriglidole is a specific inhibitor of α2-receptors. Deriglidole inhibits the binding of [3H] clonidine and [3H] imidazole x, while showing no inhibitory effect on the binding of [3H] prazosin to rat cortex and human platelet α2-adrenergic receptors. Furthermore, it demonstrates greater effectiveness than idazolide in selectively targeting peripheral receptors.[1] |
體內(nèi)活性 | In mouse pancreatic beta-cells that both deriglidole and SL86.0714 inhibit ATP-sensitive K+ channel with similar potency whereas alpha2-adrenoceptors are blocked only by deriglidole. In diabetic rats, SL84.0418 and deriglidole (10 mg/kg i.p.) fully normalized glucose tolerance whereas SL86.0714 and tolbutamide only slightly improved it. Five min after deriglidole administration in mice a marked and short lasting rise in insulin levels was observed, followed by a progressive reduction of glycemia.[2] |
存儲(chǔ)條件 | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
溶解度 | DMSO : 32.5 mg/mL (127.27 mM), Sonication is recommended. |
關(guān)鍵字 | α2 receptor | Deriglidole | AdrenergicReceptor | Adrenergic Receptor |
相關(guān)產(chǎn)品 | Amitraz | Buflomedil hydrochloride | Mirtazapine | Phenylephrine hydrochloride | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Gemfibrozil | Octopamine hydrochloride | Indacaterol | Tolazoline hydrochloride | Dexmedetomidine hydrochloride |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌化合物庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 腎上腺素能受體化合物庫 | 神經(jīng)遞質(zhì)受體化合物庫 | 神經(jīng)信號分子庫 | 抗心血管疾病化合物庫 | 內(nèi)分泌激素分子庫 | GPCR靶點(diǎn)分子庫 | 膜蛋白靶向化合物庫 |
成立日期 | 2013-04-18 (13年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP10年
|
湖北威德利化學(xué)科技有限公司
|
2025-08-04 | |
¥1500 |
VIP9年
|
湖北威德利化學(xué)試劑有限公司
|
2025-08-05 | |
¥600 |
VIP13年
|
湖北威德利化學(xué)科技有限公司
|
2025-08-05 |